摘要:
Compounds of formula (I), where: R1, R2, R3, R4 are as defined in the description, the enantiomers, diastereomers, tautomers and addition salts thereof with a pharmaceutically-acceptable acid or base. Said compounds have kinase modulating properties and are useful in the treatment of cancer, diabetes, obesity etc.
摘要:
The invention concerns compounds of formula (I), wherein: W1 represents with the carbon atoms whereto it is bound, a phenyl group or a pyridinyl group; Z represents a group selected among a hydrogen atom, halogen, a linear or branched C1-C6 alkyl, aryl, linear or branched C1-C6 arylalkyl, aryloxy, linear or branched C1-C6 arylalkoxy, hydroxy, linear or branched C1-C6 alkoxy group; R1 is such as defined in the description; R2 represents a hydrogen atom or a group of formula -CH2CH2O-R8; R3, R4 represent each a hydrogen atom, a linear or branched C1-C6 alkyl, aryl, linear or branched C1-C6 aryalkyl group; n represents an integer between 1 and 6 inclusive. The invention is useful for preparing medicines.
摘要:
The invention concerns a compound of formula (I), wherein: R1 and R2 represent each a group selected among hydrogen, alkyl, arylalkyl, hydroxy, hydroxylalkyl, dihydroxyalkyl, alkoxy, alkoxyalkyl, amino and aminoalkyl (optionally substituted); Ra and Rb represent each an alkylene chain; X1 and X2 represent each a group selected among hydroxy, alkoxy, aryloxy, arylalkoxy, alkyl, amino (optionally substituted), halogen, alkylcarbonyloxy and azido; X4 represent a methylidene group or a group of formula -Rc-X1 such as defined in their description; their isomers and their addition salts to a pharmaceutically acceptable acid or base. The invention is for use as medicines.
摘要:
The invention relates to compounds of formula (I): wherein R1 represents an alkyl or ureido group, R2 represents an alkyl group or a hydrogen atom, or R?1 and R2¿ together form a 5- or 6-membered ring, R3 represents a group CN, NO¿2?, NRaR'a, NRaSO2,R'aCZR?5¿ or CZNR¿a?R'a, R?4¿ represents a hydrogen atom or a group R3.
摘要:
The invention relates to compounds of formula (I), wherein R1 is a group selected from hydrogen, alkyl, aryl, aryalkil, heteroaryl, heteroarylalkyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, heterocycloalkoxycarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, phosphonic and Si(Ra)2Rb, Y is a group selected from HN-NH and N-R2, R3 is a hydrogen atom, an alkyl, cycloalkyl, aryl, arylalkyl group, R4 is hydrogen atom or an alkyl group, enantiomers, diastereoisomers and the salts thereof.
摘要:
Compounds of formula (I), where: R1, R2, R3, R4 are as defined in the description, the enantiomers, diastereomers, tautomers and addition salts thereof with a pharmaceutically-acceptable acid or base. Said compounds have kinase modulating properties and are useful in the treatment of cancer, diabetes, obesity etc.
摘要:
The invention relates to compounds of formula (I), where (a) is a benzyl or pyridyl group, optionally fused at position ( 2-3, 3-4, or 4-5), and optionally substituted, (W) is a X-Y or Y-X group, where (X) is a group (b) and (Y) is an oxygen atom or a (N-R3) group, n is zero or a whole number where 1 = n = 6 and G, R1, R2 and R3 are as defined in the description, the enantiomers, diastereomers and the addition salts thereof with a pharmaceutically-acceptable acid or base. The invention relates to medicaments.
摘要:
A compound selected from these of formula (I):wherein:R1 represents hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, heterocycloalkoxycarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl or phosphono,R2 represents oxygen or sulphur,R3 represents hydrogen or alkyl, cycloalkyl or arylalkyl,X represents linear or branched (C1-C6)alkylene,R4 represents a group selected from amino optionally substituted by one or two groups, -N(R3)-X1-OR5 wherein R3, X1 and R5 are as defined in the description, -N(R3)-X1-NR6R7 wherein R3, X1, R6 and R7 are as defined in the description, hydroxy, alkoxy, aryloxy, -O-X1-OR5 wherein R5 and X1 are as defined in the description, and -O-X1-NR6R7 wherein R6, R7 and X1 are as defined in the description,its isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base, and medical products containing the same which are useful in the treatment of cancer.